Candel Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead candidate, CAN-2409 (aglatimagene besadenovec), for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. This designation is intended to expedite the development and review process for regenerative medicine therapies addressing serious or life-threatening conditions. The RMAT designation was granted based on positive data from Candel's phase 3 clinical trial of CAN-2409 in combination with valacyclovir and standard of care radiation therapy. Candel aims to submit a Biologics License Application by the end of 2026, with the designation helping to facilitate the application process.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.